GlassScriptPhysician profile
Michael G Miller
NPI 1770553984
$1,945.72
in general payments reported to CMS, 2019-2025
29 companies · $491 in 2025
The $491 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $89.09 · 2021: $76.56 · 2022: $361 · 2023: $374 · 2024: $298 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $270.35 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $247.74 | 2022-2025 | |
| Abbvie INC. | $242.73 | 2019-2023 | |
| Pfizer INC. | $116.08 | 2019-2024 | |
| Exeltis, USA INC. | $103.27 | 2022-2025 | Slynd |
| Sumitomo Pharma America, INC. | $98.27 | 2023-2025 | Myfembree |
| Novo Nordisk INC | $93.38 | 2019-2025 | Wegovy |
| Hologic Sales and Service, LLC | $74.46 | 2022-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $74.05 | 2023-2024 | Veozah, Myrbetriq |
| Biogen, INC. | $71.39 | 2024-2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $55.26 | 2019-2022 | |
| Avion Pharmaceuticals | $52.15 | 2019-2021 | |
| Allergan, INC. | $43.13 | 2019-2020 | |
| Duchesnay USA Incorporated | $42.67 | 2019 | |
| Organon LLC | $42.11 | 2023-2025 | Jada System, Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $41.22 | 2024 | Paragard T 380a, Summit Doppler |
| Myovant Sciences INC. | $33.28 | 2022 | |
| Olympus America INC. | $30.63 | 2019 | |
| Therapeuticsmd, INC. | $30.13 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.08 | 2025 | Rejoyn |
| Millicent US INC | $23.20 | 2025 | Intrarosa, Femring |
| Amag Pharmaceuticals, INC. | $23.14 | 2019-2020 | |
| Exact Sciences Corporation | $21.56 | 2024 | Cologuard Collection Kit |
| Teleflex LLC | $17.96 | 2025 | Guideliner |
| Shield Therapeutics INC | $16.70 | 2024 | |
| Evofem Biosciences, INC. | $15.72 | 2023 | Phexxi |
| Almatica Pharma LLC | $14.07 | 2022 | |
| Minerva Surgical, INC | $12.34 | 2022 | |
| Davol INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.